In a recent announcement, Bristol Myers Squibb (BMS) proudly declared the successful finalization of its acquisition of RayzeBio, Inc., a prominent player in the field of radiopharmaceutical therapeutics (RPTs). With the completion of this merger, RayzeBio has become a fully owned subsidiary of BMS, marking a significant step forward for both companies. Let us delve into the facts and assess the potential impact of this acquisition on Bristol Myers Squibb.1. The Acquisition of RayzeBio:Bristol Myers Squibb successfully completed the acquisition of RayzeBio, Inc., a renowned company specializing in the development and advancement of radiopharmaceutical therapeutics. This strategic move provides BMS with immed...

RYZB's Stock Performance relative to it's Customers

RYZB's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Rayzebio Inc	962.34	0.00	0.00	52
SUBTOTAL	0.00	0.00	0.00	-

Sources: Rayzebio Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Rayzebio Inc’s corporate clients.
For your research, we’ve provided 9 tables on Rayzebio Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.